AstraZeneca is trying to outrun near-term patent cliffs with a catalyst-heavy pipeline—leveraging oncology/ADC leadership, rare-disease durability, and a new obesity push to credibly chase $80B revenue by 2030.
Overview
AstraZeneca has completed a multi-year pivot into a higher-growth, innovation-centric biopharma leader, with FY2025 and Q1 2026 results serving as validation of the model. FY2025 revenue rose to $58.7B (+8% CER), powered by broad therapeutic contributions and a higher-quality mix dominated by product sales ($55.6B). Core operating profit reached $18.5B (+9% CER) and Q1 2026 maintained +8% CER growth to $15.3B while delivering a core EPS beat ($2.58). Strategically, oncology remains the principal engine (Q1 2026 oncology revenue $6.8B, +16% CER) with strong franchises (Tagrisso, Imfinzi, Calquence) and a rapidly expanding ADC platform (Enhertu growth; Datroway launch trajectory). Rare disease adds resilient, high-margin cash flow via Ultomiris conversion and pipeline expansion. Against these positives, the investment debate centers on the Farxiga patent cliff and global pricing pressure, versus the probability that a catalyst-rich late-stage pipeline (including tozorakimab in COPD and obesity/metabolic assets) can sustain high-single-digit growth and support the $80B 2030 ambition.